Swedish Orphan patents expiration

1. Orfadin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5550165 SWEDISH ORPHAN Pharmaceutical compositions for the treatment of hereditary tyosinemia type I
Aug, 2013

(10 years ago)

US9301932 SWEDISH ORPHAN Liquid pharmaceutical composition comprising nitisinone
Feb, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-169) Sep 01, 2020

Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 18 January, 2002

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine


More Information on Dosage

ORFADIN family patents

Family Patents